AroCell announced today that the U.S. Patent and Trademark Office has granted AroCell´s patent US 10,100,128 titled ”Monoclonal Anti-TK1 Antibodies”.
The patent refers to AroCell’s proprietary monoclonal antibodies that enable the specific and sensitive measurement of Thymidine Kinase 1 in blood.
” We are delighted that the U.S. Patent and Trademark Office has granted the US patent. This reinforces our patent position in the U.S. and increases AroCell's attractiveness as business partner. We will now continue to develop our portfolio of proprietary assets to further expand its business opportunities abroad” says Johan von Heijne.
For more information:
Johan von Heijne, Acting CEO
Telephone: +46(0)705-95 15 10
AroCell is obliged to make pubic this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Johan von Heijne, at 08.30 on October 17, 2018.
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser.